Clinical and regulatory data reported in 2020 are up 24% and 47%, respectively, over the prior year, proving to be the busiest 12 months on record for the biopharma industry, in spite of, or perhaps because of, a deadly global pandemic.

Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

The top 10 biopharma stock gainers and losers for the week.

As the world begins to emerge from a horrific pandemic, armed with high-efficacy vaccines and a roadmap of lessons learned, it has become abundantly clear that dangerous infections are here to stay, and it is up to health care leaders and citizens to remain prepared and vigilant in preventing another deadly and disruptive COVID-19. During the last day of the virtual 39th Annual J.P. Morgan Healthcare Conference, two health care leaders discussed the efforts and mistakes experienced, as well as the path forward toward herd immunity and the unknown outbreaks to come.